Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today presented data showing that a test checking the methylation of a single gene, PITX2, can predict recurrence of prostate cancer in patients who have had their glands surgically removed.. The data from this study were presented at the 97th AACR Annual Meeting in Washington D.C., USA.
